GemPharmatech Co., Ltd. (SHA:688046)
China
· Delayed Price · Currency is CNY 15.37
+0.62 (4.20%)
Mar 6, 2026, 4:00 PM EST
GemPharmatech Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2018 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2018 |
| Operating Revenue | 793.25 | 686.28 | 621.73 | 515.67 | 392.44 | Upgrade
|
| Other Revenue | - | 0.56 | 0.45 | 0.87 | 1.34 | Upgrade
|
| Revenue | 793.25 | 686.84 | 622.19 | 516.55 | 393.79 | Upgrade
|
| Revenue Growth (YoY) | 15.49% | 10.39% | 20.45% | 31.17% | 50.35% | Upgrade
|
| Cost of Revenue | - | 261.33 | 202.86 | 150.22 | 101.27 | Upgrade
|
| Gross Profit | 793.25 | 425.51 | 419.33 | 366.33 | 292.51 | Upgrade
|
| Selling, General & Admin | - | 239.68 | 199.61 | 174.76 | 134.42 | Upgrade
|
| Research & Development | - | 87.13 | 96.6 | 82.93 | 55.2 | Upgrade
|
| Other Operating Expenses | 628.7 | 3.57 | 2.61 | 1.72 | 1.59 | Upgrade
|
| Operating Expenses | 628.7 | 333.68 | 307.91 | 267.94 | 196.11 | Upgrade
|
| Operating Income | 164.55 | 91.83 | 111.42 | 98.39 | 96.4 | Upgrade
|
| Interest Expense | - | -4.3 | -2.76 | -0.5 | -0.74 | Upgrade
|
| Interest & Investment Income | - | 22.39 | 28.65 | 23.73 | 14.43 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 1.69 | 0.08 | 1.49 | -0.19 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.2 | -21.56 | -20.92 | -11.32 | -16.05 | Upgrade
|
| EBT Excluding Unusual Items | 164.36 | 90.06 | 116.48 | 111.8 | 93.84 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | 2.34 | 2.73 | -0.05 | 0.32 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | 0.01 | -0.02 | -0.1 | 0.05 | Upgrade
|
| Other Unusual Items | - | 26.8 | 42.1 | 62.03 | 49.1 | Upgrade
|
| Pretax Income | 164.36 | 119.22 | 161.29 | 173.68 | 143.31 | Upgrade
|
| Income Tax Expense | 19.96 | 9.4 | 2.37 | 9.02 | 18.39 | Upgrade
|
| Earnings From Continuing Operations | 144.4 | 109.82 | 158.91 | 164.67 | 124.93 | Upgrade
|
| Net Income | 144.4 | 109.82 | 158.91 | 164.67 | 124.93 | Upgrade
|
| Net Income to Common | 144.4 | 109.82 | 158.91 | 164.67 | 124.93 | Upgrade
|
| Net Income Growth | 31.49% | -30.89% | -3.49% | 31.81% | 63.45% | Upgrade
|
| Shares Outstanding (Basic) | 413 | 407 | 407 | 392 | 357 | Upgrade
|
| Shares Outstanding (Diluted) | 413 | 407 | 407 | 392 | 357 | Upgrade
|
| Shares Change (YoY) | 1.43% | -0.18% | 3.93% | 9.84% | -1.93% | Upgrade
|
| EPS (Basic) | 0.35 | 0.27 | 0.39 | 0.42 | 0.35 | Upgrade
|
| EPS (Diluted) | 0.35 | 0.27 | 0.39 | 0.42 | 0.35 | Upgrade
|
| EPS Growth | 29.63% | -30.77% | -7.14% | 20.00% | 66.67% | Upgrade
|
| Free Cash Flow | - | -23.36 | -89.33 | -84.33 | 24.24 | Upgrade
|
| Free Cash Flow Per Share | - | -0.06 | -0.22 | -0.21 | 0.07 | Upgrade
|
| Dividend Per Share | - | 0.140 | 0.160 | 0.041 | - | Upgrade
|
| Dividend Growth | - | -12.50% | 290.24% | - | - | Upgrade
|
| Gross Margin | 100.00% | 61.95% | 67.40% | 70.92% | 74.28% | Upgrade
|
| Operating Margin | 20.74% | 13.37% | 17.91% | 19.05% | 24.48% | Upgrade
|
| Profit Margin | 18.20% | 15.99% | 25.54% | 31.88% | 31.72% | Upgrade
|
| Free Cash Flow Margin | - | -3.40% | -14.36% | -16.33% | 6.16% | Upgrade
|
| EBITDA | 237.34 | 164.62 | 157.42 | 135.68 | 125.2 | Upgrade
|
| EBITDA Margin | 29.92% | 23.97% | 25.30% | 26.27% | 31.80% | Upgrade
|
| D&A For EBITDA | 72.79 | 72.79 | 46 | 37.29 | 28.81 | Upgrade
|
| EBIT | 164.55 | 91.83 | 111.42 | 98.39 | 96.4 | Upgrade
|
| EBIT Margin | 20.74% | 13.37% | 17.91% | 19.05% | 24.48% | Upgrade
|
| Effective Tax Rate | 12.14% | 7.88% | 1.47% | 5.19% | 12.83% | Upgrade
|
| Revenue as Reported | - | 686.84 | 622.19 | 516.55 | 393.79 | Upgrade
|
| Advertising Expenses | - | 2.93 | 4.69 | 8.94 | 2.87 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.